Form 4: Royalty Pharma Director Catherine M. Engelbert Receives Stock Award

Catherine M. Engelbert, a director at Royalty Pharma plc, was granted 9,293 Class A Ordinary Shares on June 7, 2024, as part of the company's 2020 Independent Director Equity Incentive Plan.

Summary

• On June 7, 2024, Catherine M. Engelbert, a director of Royalty Pharma plc, received an award of 9,293 Class A Ordinary Shares.
• The shares were granted under the Issuer's 2020 Independent Director Equity Incentive Plan.
• These restricted stock units generally vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date.
• Following the transaction, Ms. Engelbert beneficially owns 43,514 Class A Ordinary Shares.

Sentiment

Score: 7

Explanation: The document reflects a standard stock award to a director, which is generally viewed positively as it aligns interests with shareholders. There are no apparent negative implications.

Positives

• The grant of shares to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Future Outlook

The vesting of the restricted stock units is subject to the terms of the Plan and the applicable award agreement.

Industry Context

Stock awards to directors are a common practice in publicly traded companies to incentivize and retain board members.

Stakeholder Impact

• The stock award aligns the director's interests with those of the shareholders.
• The vesting schedule may incentivize the director to contribute to the long-term success of the company.

Key Dates